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Abstract
Background: We had previously identified Ctr9, the key scaffold subunit of the human RNA polymerase II (RNAPII)
associated factor complex (PAFc), as a key factor regulating a massive ERα target gene expression and ERα-positive
breast cancer growth. Furthermore, we have shown that knockdown of Ctr9 reduces ERα protein stability and decreases
the occupancy of ERα and RNAPII at a few ERα-target loci. However, it remains to be determined whether
Ctr9 controls ERα-target gene expression by regulating the global chromatin occupancy of ERα and RNAPII
in the presence of estrogen.
Results: In this study, we determined the genome-wide ERα and RNAPII occupancy in response to estrogen treatment
and/or Ctr9 knockdown by performing chromatin immunoprecipitation coupled with high-throughput sequencing
(ChIP-seq). We found that loss of Ctr9 dramatically decreases the global occupancy of ERα and RNAPII, highlighting the
significance of Ctr9 in regulating estrogen signaling in ERα-positive breast cancer cells. Combining this resource with
previously published genomic data sets, we identified a unique subset of ERα and Ctr9 target genes, and
further delineated the independent function of Ctr9 from other subunits in PAFc when regulating transcription.
Conclusions: Our data demonstrated that Ctr9, independent of other PAFc subunits, controls ERα-target gene
expression by regulating global chromatin occupancies of ERα and RNAPII.
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Background
Estrogen receptor α (ERα) is the paramount transcrip-
tion factor in ERα-positive breast cancer, which consti-
tutes 70% of all human breast cancers. Emerging
evidence has shown that the execution of ERα signaling
cascade is through multiple pathways to regulate the
expression of ERα target genes in the presence or
absence of ligand, i.e. 17β-estradiol (estrogen; E2) [1, 2].
The genomic ERα signaling pathway involves ligand
binding, receptor dimerization and recognition of
cognate estrogen response element (ERE) which consists
of a consensus sequence containing the inverted repeat
GGTCAxxxTGACC (where x is any nucleotide), located
in either the distal or promoter regions of ERα-target
genes [1]. The ERα-dependent transcriptional program
is delicately regulated by a large number of cofactors
including pioneering factors, chromatin modifiers as well
as basal transcriptional machineries [3]. Perturbations of
ERα-dependent transcriptional networks by the aberrant
expression of ERα cofactors have been strongly linked to
breast tumorigenesis [4]. Thus, comprehensively under-
standing their mechanisms of action could lead to thera-
peutic interventions for the treatment of ERα-positive
breast cancer.
Human RNA polymerase II (RNAPII) associated factor
complex (PAFc) is composed of five subunits including
PAF1, Ctr9, Cdc73 (also known as parafibromin), Leo1,
and eukaryotic specific Ski8 (also known as WDR61) [5].
PAFc is evolutionarily conserved from yeast to Drosophila
and humans and it participates in the step-wise regulation
of transcription from transcriptional initiation, elongation,
to termination [6–8]. The PAFc regulated transcriptional
elongation is coupled with histone modifications such as
histone H2B mono-ubiquitination (H2Bub1), H3K4 tri-
methylation (H3K4me3), and H3K36 tri-methylation
(H3K36me3) via protein-protein interaction of PAFc
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subunits with the respective histone modifying enzymes
[9]. Additionally, PAFc plays a role in mRNA processing
and maturation, through the maintenance of proper poly
(A) tail length [10]. Emerging evidence has demonstrated
the diverse functions of human PAFc as well as its individ-
ual subunits in various cellular milieus. For instance, the
human PAFc is required for the maintenance of embry-
onic stem cell identity [11], neuronal migration in
mammalian brain [12], antiviral and pro-inflammatory
response [13], and oncogenesis regulation [14, 15]. Our
studies have demonstrated the involvement of Ctr9, a key
scaffold subunit of human PAFc, in ERα-positive breast
cancer progression and ERα target gene expression [16].
Specifically, using loss-of-function approach, we observed
that depletion of Ctr9 led to apparent morphological
change, decrease of proliferation, reduced colony forma-
tion, and impaired ERα-target gene expression in ERα-
positive breast cancer cells [16]. Moreover, Ctr9 regulates
ERα protein stability and facilitates RNAPII recruitment
and transcription-coupled histone modifications such as
H2Bub1, H3K27ac, and H3K36me3 at the selected ERα
targets [16]. However, the global control of Ctr9 on ERα
occupancy and RNAPII recruitment awaits investigation
to deeply understand the functional significance of Ctr9 in
ERα transcription network in breast cancer.
Profiling the genome-wide RNAPII and ERα chroma-
tin occupancy affected by Ctr9 is advantageous over
gene expression study to elucidate the global effects of
Ctr9 on ERα-dependent transcriptional program and to
identify the target genes regulated by Ctr9. In agreement
with several published gene expression studies in MCF7
cells [17–28], our gene expression profiling identified
less than 2000 E2-responsive genes [16, 29]. This is in
contrast to the large scale ERα ChIP profiling where
much more ERα binding sites across the genome were
identified [18, 19, 21, 23, 25, 30–32]. For example, the
Myles Brown lab identified 3665 ERα binding sites [25]
and the Hendrik G Stunnenberg lab identified 10,205
ERα binding sites [32] in response to E2 treatment, by
ChIP-chip and ChIP-seq, respectively. The discordance
in E2-responsive transcription and ERα binding events is
probably due to the prevalence of enhancers over pro-
moters in regulating transcription and also suggests that
some ERα binding events do not fulfill gene regulation.
In addition, the mRNA level of a target gene may not
faithfully reflect the transcriptional event due to the
mRNA degradation. Therefore profiling the genome-
wide RNAPII occupancy would provide a direct readout
of transcriptional activity and thus yield mechanistic
insights into the transcriptional regulation by estrogen
and Ctr9 in ERα-positive breast cancer.
In this study, we performed chromatin immunoprecip-
itation followed by massive parallel sequencing (ChIP-
seq) and demonstrated that Ctr9 knockdown (KD) elicits
global decrease of the genome-wide occupancy of ERα
and RNAPII, consistent with the function of Ctr9 in
regulating ERα protein stability and ERα target gene
expression. Integrative analyses of the ChIP-seq and
microarray gene expression data sets identified the pri-
mary ERα and Ctr9 target genes, which have prognostic
value of breast cancer outcome. Comparative analysis of
RNAPII genome-wide occupancy alteration resulted
from Ctr9 KD and PAF1 KD provided the first line of
evidence in support of the PAFc independent function of
Ctr9 on transcription regulation.
Results
Ctr9 knockdown triggers genome-wide decrease of ERα
occupancy
To investigate the estrogen and Ctr9 mediated transcrip-
tion regulation in ERα-positive breast cancer cells, we
used the MCF7-tet-on-shCtr9 inducible knockdown cell
line previously developed in our lab as a model system
(Fig. 1a) [16, 33]. ChIP-seq was first performed using an
anti-ERα antibody in MCF7-tet-on-shCtr9 cells pre-
treated with vehicle or doxycycline (Dox) followed by
DMSO control or E2 induction. Classical ERα target
genes, such as TFF1 and GREB1, showed significant en-
richment of ERα over a narrow range in their enhancer
and promoter regions in response to E2 treatment
(Fig. 1b and c), These results are highly consistent with
several previous reports [18, 25, 32]. Consistent with our
previous ChIP-qPCR results [16], we found that Ctr9
KD by Dox treatment significantly reduced ERα binding
at the enhancer and promoter regions of TFF1 and
GREB1 genes (Fig. 1b and c).
In accordance with others’ findings that substantial ERα
binding is induced by estrogen treatment [25, 32], we
identified a total of 5264 significant ERα binding sites
upon E2 induction (Fig. 2a). We visually inspected the
genomic locations of these 5264 ERα binding sites using
Cistrome [34], and found that the majority of the binding
sites are located within introns (42.1%) or distal regions
(44.4%) and only a small percentage (7.0%) in promoter
regions (Additional file 1: Figure S1) in agreement with
previous reports [23, 25, 32], validating the reliability of
our ChIP-seq datasets. Comparison between the four
treatment conditions revealed that, in the presence of E2,
Ctr9 KD decreased ERα binding at 3330 sites and only
increased ERα binding at 26 sites (Fig. 2a), suggesting that
Ctr9 is in general a positive regulator of genome-wide
ERα occupancy. Aggregate plots further confirmed that
loss of Ctr9 dramatically decreased the genome-wide ERα
binding (Fig. 2b). As a further support, the heatmaps of
ERα ChIP-seq density showed that Ctr9 depletion signifi-
cantly reduced ERα occupancy at the majority of ERα
binding sites (Fig. 2c). To obtain a more intuitive view of
the effect of Ctr9 KD on global ERα binding, we
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performed a Venn diagram analysis for 5264 E2-induced
ERα binding sites in control cells, 2848 E2-induced ERα
binding sites in Ctr9 KD cells, and 3330 ERα binding sites
decreased by Ctr9 KD (Fig. 2d). Among the E2-induced
ERα binding sites in control cells, 1630 was significantly
reduced by Ctr9 KD, although E2 treatment can still
induce the binding of ERα at these sites (Fig. 2d). Much
stronger effect was observed for 1572 ERα binding sites
where Ctr9 KD almost completely abrogated the ERα
binding (Fig. 2d). Therefore, we termed the 1630 sites and
1572 sites less and more sensitive to Ctr9 KD, respectively.
ERE motif analyses identified that 65 and 55% of these
two groups of ERα cistrome contains at least half ERE,
respectively. We had previously shown that Ctr9 KD de-
creased ERα protein level thus expected reduced ERα
occupancy on all targets. These results instead support the
notion that Ctr9 elicits target-specific regulation towards
ERα target genes, underscoring the complexity of Ctr9
function in the regulation of ERα-mediated transcriptional
program beyond its conventional roles in the PAFc to
regulate transcription initiation and elongation.
Ctr9 knockdown alters the repertoire of ERα cistrome as
illustrated by motif analyses
Next, we further investigated the impact of Ctr9 KD on
ERα cistrome. We interrogated the sequence of the
aforementioned three groups of ERα binding sites
(Fig. 2d) for overrepresentation of DNA motifs using the
MEME suite [35]. As expected, the most prevalent
motifs at the ERα binding sites in all three groups are
EREs (Fig. 2e, No. 1). Moreover, among the top five
DNA motifs for E2-induced ERα cistrome, we found
significant enrichment of DNA sequences featuring pro-
gesterone responsive element (PRE) (Fig. 2e, No. 3) and
FOXA1 binding motif (Fig. 2e, No. 5). These results are













































Fig. 1 ERα occupancy at selected ERα target genes. a Schematic representation of the design of doxycycline (Dox) inducible Ctr9 knockdown in
MCF7 cells. b Representative genome browser views of ERα ChIP-seq profiles at TFF1 gene under the four indicated treatment conditions.
c Representative genome browser views of ERα ChIP-seq profiles at GREB1 gene under the four indicated treatment conditions
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receptor associates with ERα and modulates ERα action
in breast cancer [31], and FOXA1 is the pioneer factor
for shaping the genome-wide distribution of ERα [36],
respectively. Importantly, PREs are no longer enriched
in the E2-induced ERα cistrome in the context of Ctr9
KD, this is consistent with our previous finding that
Ctr9 KD significantly decreases the expression of pro-
gesterone receptor [16]. Furthermore, all three groups of
ERα cistrome displayed overlapping yet different DNA
motif enrichment, suggesting that Ctr9 might affect or
cooperate with other factors to regulate ERα action and
estrogen signaling in ERα-positive breast cancer.
Ctr9 positively regulates RNA polymerase II binding in
MCF7 cells
Given that the vast majority of ERα binding sites are
located at great distances from the annotated genes
(Additional file 1: Figure S1), identification of ERα direct
target genes simply based on the ERα binding sites has
been problematic. To identify genes in response to E2
and/or Ctr9 KD in a more intuitive manner, we per-
formed ChIP-seq for RNAPII in MCF7-tet-on-shCtr9
cells under four different conditions (Vehicle, DMSO;
Vehicle, E2; Dox, DMSO; Dox, E2). RNAPII occupancy
throughout the gene body represents a direct readout of
the transcriptional activity and thus provides more
intuitional evidence for estrogen and Ctr9 mediated
transcription regulation. Classical ERα target genes, for
example TFF1 and GREB1, showed a dramatic increase
of RNAPII occupancy over their enhancer, promoter,
and gene body regions upon E2 treatment (Fig. 3a). Ctr9
KD by Dox treatment significantly reduced RNAPII
occupancy at the aforementioned regions of TFF1 and
GREB1 genes (Fig. 3a), in line with our previous ChIP-
qPCR results and microarray gene expression results
[16]. Genomic location analysis of E2-induced RNAPII
binding sites showed that unlike ERα, RNAPII binding
displayed more dispersed occupancy across the genome
(Additional file 1: Figure S2).
At a global scale, E2 treatment and Ctr9 KD triggered
redistribution of genome-wide RNAPII binding pattern
(Fig. 3b). To directly identify genes responding to E2
treatment and/or Ctr9 KD, we first defined RNAPII-
target gene using the criteria that one or more RNAPII
binding sites can be found within its gene body (TSS,
TTS, 5′-UTR, exon, intron, and 3′-UTR). Comparisons
between the different conditions showed that, in re-
sponse to E2 treatment, 2353 genes showed an increase
and 562 genes showed a decrease in RNAPII occupancy
(Fig. 3c). In contrast, E2 stimulation only increased
RNAPII occupancy over 894 genes in Ctr9 KD cells
(Fig. 3c), suggesting that Ctr9 positively regulates E2-
induced RNAPII binding. The positive regulatory role of
Ctr9 was further supported by the decrease of RNAPII
occupancy over thousands of genes upon Ctr9 KD
(Fig. 3c). Aggregate plot also confirmed that loss of Ctr9
significantly decreased the genome-wide RNAPII occu-
pancy particularly at the transcription start sites
(TSS) (Fig. 3d). We previously performed microarray
gene expression analysis in MCF7-tet-on-shCtr9 cells
treated with vehicle or Dox followed by DMSO control
or E2 induction to identify E2 and Ctr9 regulated tran-
scriptome [16, 29]. To gain additional insights into the
regulation of RNAPII occupancy by Ctr9, we further ex-
amined the RNAPII occupancy for Ctr9 KD decreased
and increased genes selected from our microarray data
set (Fig. 3e). Aggregate plots showed that RNAPII occu-
pancy was drastically decreased by Ctr9 KD for Ctr9 KD
decreased genes, while increased particularly within the
gene body by Ctr9 KD for Ctr9 KD increased genes, sug-
gesting the context dependent role of Ctr9 in regulating
RNAPII occupancy in MCF7 cells. To directly assess the
impact of Ctr9 KD on estrogen signaling, we compared
the genes with RNAPII binding increased by E2 treat-
ment and genes with RNAPII binding decreased by Ctr9
KD in the presence of E2 (Fig. 3f ). The Venn diagram
analysis showed that about half of E2-responsive genes
(1156 genes) displayed RNAPII binding decrease upon
Ctr9 KD (Fig. 3f ). Besides, Ctr9 KD also decreased
RNAPII occupancy at 1583 non-E2-responsive genes
(Fig. 3f ), suggesting that Ctr9-dependent RNAPII chro-
matin occupancy is not restricted to the estrogen regu-
lated genes in breast cancer.
Integrative analyses of the combined ChIP-seq and
microarray data reveal the ERα and Ctr9 signature
which has clinical significance
To directly identify ERα and Ctr9 targets, we performed
integrative analyses of the combination of ChIP-seq and
microarray data. Comparing genes with RNAPII binding
increased by E2 and genes with increased expression
upon E2 treatment revealed an overlap of 279 genes,
(See figure on previous page.)
Fig. 2 Ctr9 knockdown decreases genome-wide ERα occupancy. a A matrix describing the approach used to identify differential ERα binding
sites. b Aggregate plot showing the genomic binding profiles of ERα on ERα binding regions under the indicated four treatment conditions. c
Heatmaps showing the ERα occupancy on ± 5 kb of ERα binding peak centers in the indicated four treatment conditions. The black arrow
denotes the center of ERα binding peaks. d Venn diagram showing the overlaps between E2-induced ERα binding sites, E2-induced ERα
binding sites in the context of Ctr9 knockdown (KD), and Ctr9 KD decreased ERα binding sites in the presence of E2. e De novo motif
analyses of the three sets of ERα binding sites noted in (d)
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termed E2-activated genes (Fig. 4a and Additional file 2:
Table S1). Further comparing with genes with ERα bind-
ing increased by E2 treatment identified 88 common
genes among the three groups including some well-
known ERα target genes such as TFF1 and GREB1
(Fig. 4a and Additional file 2: Table S1). Thus, we de-
fined the 88-gene set as primary ERα target signature.
Note that many genes with increased expression upon
E2 treatment failed to display elevated RNAPII binding
(Fig. 4a), probably because ChIP-seq with short E2 treat-
ment (45 min) predominantly identifies early responsive
target genes whereas gene expression profiling at 4 h
after E2 treatment identifies the late responsive and
some indirect targets. As ERα signature, the identified
88 gene set is highly expressed in ERα-positive human
breast tumors (Fig. 4b) and the high expression level of
the ERα signature is associated with poor overall survival
in ERα-positive, lymph node-negative breast cancer
patients (Fig. 4c).
Given that ERα-positive breast cancer depends on
estrogen for growth and target gene transcription regula-
tion, we next sought to identify primary Ctr9 targets in
the presence of E2 by comparing genes with RNAPII
binding decreased by Ctr9 KD and genes with decreased
expression upon Ctr9 KD (Fig. 4d). The Venn diagram
analysis identified 240 common genes between these
two data sets. We defined the 240 gene set as Ctr9
signature (Fig. 4d and Additional file 2: Table S1). To
determine if the Ctr9 signature has a broader clinical
significance, we mined breast cancer outcome-linked
gene expression data using the Gene Expression-Based
Outcome for Breast Cancer Online (GOBO) tool [37]. In
line with our previous finding that Ctr9 is highly
expressed in ERα-positive breast cancer [16], the Ctr9
signature is also enriched in ERα-positive breast tumors
(Fig. 4e). Kaplan-Meier analysis demonstrated that high
expression levels of the Ctr9 signature strongly associ-
ates with poor overall survival in ERα-positive, lymph
node-negative breast cancer patients (Fig. 4f ), further
highlighting the functional significance of Ctr9 in human
breast cancer. Furthermore, comparing the Ctr9 signa-
ture with E2-responsive genes revealed an overlap of 59
genes (Fig. 4g and Additional file 2: Table S1). Taken to-
gether, these integrative analyses provided a deeper
understanding of estrogen and Ctr9 regulated transcrip-
tome in ERα-positive breast cancer cells.
Distinct roles of Ctr9 in regulating RNAPII occupancy
independent of PAFc
Our previous study implies that Ctr9 might function in-
dependently of the other subunits of PAFc in regulating
target gene expression and breast cancer progression
[16]. To further distinguish the functions of Ctr9 from
the other PAFc subunits, we analyzed recently published
RNAPII ChIP-seq data obtained in wild-type and PAF1
KD MCF7 cells cultured in complete medium [38]. Simi-
lar to Ctr9 KD, PAF1 KD resulted in decrease of RNAPII
occupancy over 5135 genes and increase over only 190
genes (Fig. 5a), suggesting that PAF1 is a positive regulator
of RNAPII genomic binding in MCF7 cells. Aggregate plot
and heatmap of ChIP-seq density also confirmed that loss
of PAF1 significantly decreases genome-wide RNAPII
occupancy (Fig. 5b and c). To examine whether PAF1 and
Ctr9 exhibit the same regulation on genome-wide RNAPII
occupancy, we compared the genes that elicited decreased
RNAPII binding by knocking down PAF1 and Ctr9; the
results showed an overlap of 1325 genes (Fig. 5d). Interest-
ingly, a large number of PAF1 regulated genes and Ctr9
regulated genes are mutually exclusive (Fig. 5d), indicating
that Ctr9 functions independently from PAF1. Similarly,
comparison of genes that elicited increased RNAPII
binding by knocking down PAF1 and Ctr9 revealed only
12 common genes (Fig. 5e). Taken the Ctr9 target gene
IGFBP4 and GREB1 as examples, Ctr9 KD dramatically
decreased the occupancy of RNAPII across the gene body
whereas PAF1 KD elicited no effect on RNAPII occupancy
at IGFBP4 gene and increased RNAPII occupancy at
GREB1 gene, respectively (Fig. 5f). To further validate our
ChIP-seq findings, we performed validation experiments
by ChIP-qPCR to examine the RNAPII occupancy at the
transcription start site (TSS) and transcribed region (TR)
of GREB1 and IGFBP4 genes in MCF7 cells stably
expressing control shRNA or shRNAs targeting Ctr9,
Cdc73, Ski8, and PAF1 (Fig. 6). The results showed that
Ctr9 KD with two independent shRNAs (shCtr9 #3 and
shCtr9 #5) significantly reduced the RNAPII occupancy at
TSS and TR regions of GREB1 and IGFBP4 genes,
whereas KD of the other PAFc subunits elicited little effect
(See figure on previous page.)
Fig. 3 Ctr9 knockdown decreases genome-wide RNA polymerase II occupancy. a Representative genome browser views of RNA polymerase II
(RNAPII) ChIP-seq profiles at TFF1 and GREB1 genes under the four indicated treatments. b A matrix describing the approach used to identify
differential RNAPII binding peaks. c A matrix describing the approach used to identify genes with differential RNAPII binding peaks. RNAPII-bound gene is
defined as gene that contains one or more RNAPII binding peaks within the gene body. d Metagene analysis showing total RNAPII occupancy measured
by ChIP-seq in cells under the four indicated treatments. All RNAPII-bound genes were normalized to same length with 2 kb extended upstream from
TSS and 2 kb downstream from TTS for analyzing the average density. TSS, transcription start site; TTS, transcription termination sites. e Metagene analyses
showing total RNAPII occupancy measured by ChIP-seq for Ctr9 knockdown decreased genes (upper) and increased genes (bottom) selected from the
microarray gene expression data set. f Venn diagram showing the overlap between genes with RNAPII binding increased by E2 treatment and genes
with RNAPII binding decreased by Ctr9 KD in the presence of E2
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on the RNAPII occupancy at the same regions (Fig. 6).
Altogether, these findings suggest that Ctr9 may have a
unique role in regulating RNAPII chromatin association
independent of PAFc.
Discussion
Estrogen signaling in ERα-positive breast cancer is
tightly regulated by ERα itself as well as its associated
co-regulator proteins. It is essential to understand the
ERα target gene network and the transcription regula-
tion mechanisms. In this study, we have applied ChIP-
seq to determine the genome-wide alterations of ERα
and RNAPII occupancy in response to E2 induction
and/or KD of Ctr9. The major finding is that loss of
Ctr9 led to dramatic decrease of genome-wide occu-
pancy of both ERα and RNAPII, supporting a positive
regulatory role of Ctr9 in mediating estrogen-dependent
transcriptional regulation. Integrative analyses of the
combined ChIP-seq and microarray gene expression data
led to the identification of 88 primary ERα targets and
240 primary Ctr9 targets which both have significant
clinical relevance. We acknowledge that ChIP-seq for
Ctr9 in MCF7 cells could provide a more precise identi-
fication of direct Ctr9 target genes. However, Ctr9 ChIP-
seq has been technically challenging. We performed the
Ctr9 ChIP-seq using the commercially available anti-
Ctr9 antibody. However, ChIP-seq signals were very
weak with less than 30 peaks identified (data not shown).
This is consistent with the report by Fei Xavier Chen, et
al. [38] in which this anti-Ctr9 antibody also failed in
ChIP-seq. Therefore, ChIP-grade antibodies for Ctr9
need to be developed for future ChIP-seq experiments.
Emerging evidence has shown that some transcrip-
tional cofactors can exert a global impact on ERα target
gene expression and/or genome-wide ERα binding [18,
36, 39–41]. For example, loss-of-function approach
coupled with gene expression microarray profiling dem-
onstrated that BRD4, KDM3A, and Cohesin are required
for the expression of a large portion of ERα target genes
[18, 40–42]. GATA3 and FOXA1 have been implied as
the pioneer factors for priming the genome-wide
distribution of ERα [36, 39]. Although Ctr9 acts as a
master regulator of estrogen signaling by stabilizing ERα
protein [16], controlling genome-wide ERα and RNAPII
binding, and affecting the target gene expression, the
importance of Ctr9 in the estrogen signaling network
orchestrated by the family of transcriptional factors and
cofactors is of great interest and awaits future investiga-
tion. In this regard, our genomic analyses performed in
this study provided valuable resources for possible
comparison with the other factors regulating ERα tran-
scriptome. Moreover, given that ERα protein level is
regulated by Ctr9, we cannot distinguish whether the
global change in ERα cistrome upon Ctr9 KD is specific
to loss of Ctr9 or is due to reduced ERα protein itself,
which awaits further clarification in the future.
Our previous study has also shown that Ctr9 modu-
lates MCF7 cell morphology, cell proliferation, and ERα
target gene expression [16]. However, we could not
distinguish whether Ctr9 functions independently or in
the context of PAFc. Here, by comparing the alterations
in RNAPII occupancy resulted from PAF1 KD and Ctr9
KD, we provided the first evidence showing that PAF1
and Ctr9, despite both positively regulate genome-wide
RNAPII binding, might regulate RNAPII binding
through different mechanisms in MCF7 cells. Moreover,
ChIP-seq analyses in human acute myeloid leukemia
THP1 cells showed that PAF1 occupancy generally over-
laps with the promoter-proximal RNAPII peaks whereas
Ctr9 occupancy does not [43], reinforcing the PAFc
independent functions of Ctr9.
Conclusions
In this study, we profiled the genome-wide binding
patterns of ERα and RNAPII in response to estrogen
stimulation and/or Ctr9 KD. We showed that Ctr9
acts as a master regulator of the gene transcription
program in ERα-positive breast cancer cells by affect-
ing the global occupancy of ERα and RNAPII. Com-
bination of ChIP-seq and the previous microarray
gene expression data revealed primary target genes of
ERα and Ctr9. Moreover, comparing RNAPII binding
(See figure on previous page.)
Fig. 4 Integrative analyses of ChIP-seq and microarray gene expression data sets identify primary ERα and Ctr9 targets. a Venn diagram showing
the overlaps between genes with ERα binding increased by E2 treatment, genes with RNAPII binding increased by E2 treatment, and genes with
increased expression upon E2 treatment identified from microarray analysis. b Box plots displaying the mRNA expression of primary ERα target
gene signature between ERα- (n = 395) and ERα + (n = 1225) breast tumors. The gene expression data were accessed using the Gene Expression-
Based Outcome for Breast Cancer Online (GOBO) tool. c Kaplan-Meier survival analysis displaying the relationship between overall survival time
and the primary ERα target gene signature in ERα+, lymph node negative (LN-) breast cancer patients. The breast cancer outcome-linked gene
expression data were accessed using the GOBO tool. d Venn diagram showing the overlap between genes with RNAPII binding decreased by
Ctr9 knockdown and genes with decreased expression upon Ctr9 knockdown identified from microarray analysis in the presence of E2. e Box
plots displaying the mRNA expression of Ctr9 target gene signature between ERα- (n = 395) and ERα + (n = 1225) breast tumors. The gene expression
data were accessed using the GOBO tool. f Kaplan-Meier survival analysis displaying the relationship between overall survival time and the Ctr9 target
gene signature in ERα+, LN- breast cancer patients. The breast cancer outcome-linked gene expression data were accessed using the GOBO tool.
g Venn diagram showing the overlap between the 240 Ctr9 target genes noted in (d) and the 279 E2-activated genes noted in (a)
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alterations between Ctr9 KD and PAF1 KD identified
a unique subset of Ctr9 target genes that implicate
PAFc-independent function of Ctr9. Altogether, our
study provides a molecular basis to further under-
stand the transcriptional control in ERα-positive
breast cancers.
Fig. 5 Overlapped and distinct roles of PAF1 and Ctr9 in RNA polymerase II chromatin association. a Schematic representation of the number of
genes with differential RNAPII binding in PAF1 knockdown MCF7 cells (shPAF1) as compared to control cells (shScr). b Metagene analysis showing
total RNAPII occupancy measured by ChIP-seq in cells transduced with shScr (control) or shPAF1. All RNAPII-bound genes were normalized to same
length with 2 kb extended upstream from TSS and 2 kb downstream from TTS for analyzing average density. TSS, transcription start
site; TTS, transcription terminal sites. c Heatmap showing RNAPII occupancy at all genes in PAF1 knockdown (shPAF1) and control
(shScr) conditions. d Venn diagram showing the overlap between genes with RNAPII binding decreased by PAF1 knockdown and
genes with RNAPII binding decreased by Ctr9 knockdown. e Venn diagram showing the overlap between genes with RNAPII binding
increased by PAF1 knockdown and genes with RNAPII binding increased by Ctr9 knockdown. f Representative genome browser views
of RNAPII ChIP-seq profiles at IGFBP4 and GREB1 genes in the indicated conditions
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Methods
Cell culture
MCF7-tet-on-shCtr9 cells were generated previously
[33] and maintained in Dulbecco’s modified medium
(DMEM) (Life Technologies) supplemented with 10%
fetal bovine serum (FBS) (Life Technologies). Cells were
cultured at 37 °C in a humidified atmosphere containing
5% CO2. Doxycycline (Dox) was purchased from
Fig. 6 PAFc-independent role of Ctr9 in RNA polymerase II chromatin association at GREB1 and IGFBP4 genes assessed by ChIP-qPCR. a ChIP-qPCR
analyses of the occupancy of RNAPII on the TSS or TR of GREB1 and IGFBP4 genes in MCF7 cells stably expressing control shRNA or shRNAs targeting
Ctr9, Cdc73, Ski8, and PAF1 treated with DMSO or 10 nM E2 for 45 min. b ChIP-qPCR analyses of the occupancy of IgG control on the TSS or TR of
GREB1 and IGFBP4 genes in MCF7 cells stably expressing control shRNA or shRNAs targeting Ctr9, Cdc73, Ski8, and PAF1 treated with DMSO or 10 nM
E2 for 45 min. ChIP-qPCR data were normalized to input DNA qPCR data and expressed as “percent of input”; data are represented as mean ± SD. n= 3
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Clontech (Mountain View, CA) and used at a final con-
centration of 500 ng/ml. Dimethyl sulfoxide (DMSO)
and 17 β-estradiol (E2) were purchased from Sigma (St.
Louis, MO). Prior to chromatin immunoprecipitation
(ChIP) assays, MCF7-tet-on-shCtr9 cells were cultured
in DMEM supplemented with 10% FBS in the absence
or presence of 500 ng/mL Dox for 4 days, followed by
continuing cultured in phenol red-free DMEM supple-
mented with 5% charcoal-dextran-treated FBS in the
absence or presence of 500 ng/mL Dox for another
3 days. Cells were then treated with DMSO or 10 nM E2
for 45 min. Antibodies used for ChIP-seq in this study
were anti-ERα (sc-543, HC-20) purchased from Santa
Cruz Biotechnology and anti-RNA polymerase II (#05-
623, clone CTD4H8) purchased from Millipore.
Chromatin immunoprecipitation (ChIP)
ChIP assays were performed as described previously [16].
In detail, cells were grown in 15-cm dish as described above
and cross-linked for 10 min at room temperature by the
addition of 37% formaldehyde stock solution to the cell
culture media to achieve a final concentration of 1%.
Crosslink was quenched for 5 min at room temperature by
the addition of glycine to a final concentration of 0.125 M
followed by two washes with ice-cold PBS. Cells were
scraped, collected by centrifugation and subjected to cell
lysis in lysis buffer 1 (10 mM HEPES pH 7.0, 10 mM
EDTA, 0.5 mM EGTA, 0.25% Triton X-100, supplemented
with 0.5 mM PMSF before use) with rotation for 10 min at
4 °C. The crude nuclear pellets were collected by centrifu-
gation (1500 rpm, 4 °C, 4 min), washed with lysis buffer 2
(10 mM HEPES pH 7.0, 200 mM NaCl, 1 mM EDTA,
0.5 mM EGTA, supplemented with 0.5 mM PMSF before
use) with rotation for 10 min at 4 °C. Nuclear pellets were
collected by centrifugation (1500 rpm, 4 °C, 4 min), resus-
pended in nuclear lysis buffer [50 mM Tris–HCl pH 8.1,
10 mM EDTA, 1% SDS, supplemented with 1 mM PMSF
and 1 × protease inhibitor cocktail (Sigma-Aldrich) before
use] and incubated on ice for 10 min. The chromatin was
sheared by sonication in ice-water bath at 4 °C using a
Branson Sonifier 450 with a microtip (40% amplitude, 3 s
on, 10 s off, 5 min total pulse time). Sonicated nuclear ly-
sates were cleared by centrifugation (15,000 rpm, 10 °C,
15 min) and nuclear protein concentration was determined
using the BioRad Protein Assay (BioRad). Equal amounts of
total nuclear proteins were used for ChIP and supple-
mented with corresponding volume of nuclear lysis buffer
to achieve same final volumes between different samples,
and then diluted 1:10 with dilution buffer (20 mM Tris–
HCl pH 8.1, 150 mM NaCl, 2 mM EDTA, 1% Triton X-
100, supplemented with 1 × protease inhibitor cocktail
before use). Five percent of the material was removed and
saved as input, and the rest was incubated overnight at 4 °C
with the antibody of interest or a normal IgG control.
The following day, the immune complexes were
collected by adding Dynabeads Protein A or Dynabeads
M-280 Sheep anti-Mouse IgG (Life Technologies) (beads
were pre-washed with ChIP dilution buffer three times
before use) and incubating with rotation for 2 h at 4 °C.
The immunoprecipitated material was subsequently
washed once with low salt wash buffer (20 mM Tris–
HCl pH 8.1, 150 mM NaCl, 2 mM EDTA, 0.1% SDS,
1% Triton X-100), once with high salt wash buffer
(20 mM Tris–HCl pH 8.1, 500 mM NaCl, 2 mM EDTA,
0.1% SDS, 1% Triton X-100), once with LiCl wash buf-
fer (10 mM Tris–HCl pH 8.1, 0.25 M LiCl, 1 mM
EDTA, 1% NP-40, 1% deoxycholate), and twice with TE
buffer (10 mM Tris–HCl pH 8.0, 1 mM EDTA pH 8.0).
Each wash was done with rotation for 5 min at 4 °C
followed by separation on magnetic stand. The immu-
noprecipitated material was eluted twice at room
temperature in freshly prepared elution buffer (1% SDS,
0.1 M NaHCO3) by shaking on a vortexer for 20 min.
The eluted material and the input material were then
digested with proteinase K (200 μg/ml final concentra-
tion) for 2 h at 55 °C, and the crosslinks were reversed
overnight by incubating at 65 °C in a hybridization oven.
DNA was purified using a Qiagen PCR Purification Kit
according to the manufacturer’s protocol.
ChIP-seq library preparation
Prior to ChIP-seq library preparation, ChIPed DNA
samples were submitted to the Sequencing Facility at
University of Wisconsin Madison Biotechnology Center
for determining DNA concentration and size distribu-
tion, using Qubit Fluorometer (Thermo Fisher Scientific)
and Agilent High Sensitivity DNA Kit (Agilent Tech-
nologies), respectively. 10 ng of ChIPed DNA from each
condition was used to generate ChIP-seq library using
the Ovation Ultralow System V2 1–16 Kit (NuGEN
Technologies), according to the manufacturer’s protocol.
Briefly, the DNA was end-repaired and subsequently
ligated to Illumina sequencing adaptors. The ligated
DNA was purified using the Agencourt RNAClean XP
bead (Beckman Coulter). A subsequent PCR amplifica-
tion step (15 cycles) added additional linker sequence to
the purified fragments to prepare them for annealing to the
Genome Analyzer flow-cell. Following PCR amplification,
the library was size selected to a narrow range of fragment
sizes by separation on a 2% agarose gel (120 V, 1.5 h) and a
band between 300–500 bp was excised. The library was
purified from the excised agarose using the Qiagen MiniE-
lute PCR Purification Kit, according to the manufacturer’s
protocol. Purified libraries were then submitted to the
Sequencing Facility at University of Wisconsin Madison
Biotechnology Center for quality control to determine the
size, purity, and concentration of the final ChIP-seq librar-
ies. Qualified libraries were submitted to New York
Zeng et al. BMC Genomics  (2016) 17:902 Page 12 of 14
Genome Center (NYGC) for deep sequencing using an
Illumina HiSeq 2000 per the manufacturer’s instructions.
ChIP-seq data analyses
ChIP-seq raw data were obtained from NYGC, and the
reads were mapped to the human reference genome
(UCSC hg19) using Bowtie (version 2.1.0) [44] using de-
fault parameters. ChIP-seq raw peaks were visualized in
Integrative Genomics Viewer (IGV) (version 2.3.40) [45].
Peak calling was done by Model-based Analysis of ChIP-
seq (MACS) (version 1.4.2) [46] using default parameters
and by taking one treatment group as control and com-
paring the other treatment group to the corresponding
control. Coverage was determined by normalizing the
total number of mapped reads per hundred million.
MEME suite (version 4.10.1) was used for motif discovery.
The ±100 bp around a peak summit was used for motif
discovery. Annotated genes with its 50 kb upstream that
overlapped with ERα peaks were defined as ERα target
genes. Annotated genes with their gene body overlapped
with RNAPII peaks were defined as RNAPII target genes.
For plots of ChIP reads over gene bodies, each gene
was divided into 20 intervals (5% each interval) separ-
ately for the body of the genes, 2 kb upstream of the
TSS, and 2 kb downstream of the TTS. Normalized
ChIP read density for each interval was plotted. Stan-
dardized z-scores were used in heatmap visualization.
Primers used in ChIP-qPCR experiments
GREB1 TSS F: 5′-GCCAAATGGAAGAAGGACAG-3′
GREB1 TSS R: 5′-ACCACCTACCTCCAGTCACC -3′
GREB1 TR F: 5′-CCCAAGCCTTCTCTGGGTTC-3′
GREB1 TR R: 5′-AGCAGACGAGAAGTAGGGCT-3′
IGFBP4 TSS F: 5′-GGTGTGGCCAGGGACCGGTA
TAAA-3′
IGFBP4 TSS R: 5′- AAGTTAGCAGGCGTGCCG
GA-3′
IGFBP4 TR F: 5′-TTGGGGAGGATGAGGGAGTG-3′
IGFBP4 TR R: 5′-CCTCAACGCCAAAGTCCCTC
TA-3′
Additional files
Additional file 1: Figure S1. Genomic location of E2-induced ERα binding
sites. Figure S2. Genomic location of E2-induced RNAPII binding sites.
(DOCX 922 kb)
Additional file 2: Table S1. Identification of ERα and Ctr9 targets by
analyzing the ChIP-seq and microarray data sets. (XLSX 15 kb)
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